First tablet for dengue reveals promise in human problem trial

Oct 20 (Reuters) – A tablet for dengue fever developed by Johnson & Johnson (JNJ.N) appeared to guard in opposition to a type of the virus in a handful of sufferers in a small human problem trial in the USA, in line with information introduced by the corporate on Friday.

There are presently no particular therapies for dengue, a rising illness risk, the corporate mentioned forward of presentation of the info on the American Society of Tropical Drugs and Hygiene Annual Assembly in Chicago.

“It’s the first ever to point out antiviral exercise in opposition to dengue,” Marnix Van Loock, who oversees rising pathogens analysis for J&J’s Janssen division, mentioned of the drug.

In human problem trials, researchers deliberately expose wholesome volunteers to a pathogen to check a vaccine or remedy, or higher perceive the illness they trigger.

Dengue fever, whereas typically asymptomatic, is also called “break bone fever” for the severity of the joint ache and spasms that some sufferers expertise.

It has lengthy been a scourge throughout a lot of Asia and Latin America, inflicting tens of millions of infections every year and tens of hundreds of deaths, and is more likely to unfold additional as local weather change makes extra areas hospitable for the mosquitoes that unfold it, the World Well being Group’s chief scientist Jeremy Farrar mentioned earlier this month.

Within the trial finished with Johns Hopkins Bloomberg Faculty of Public Well being, 10 volunteers got a excessive dose of the J&J tablet 5 days earlier than being injected with a kind of dengue. They continued to take the tablet for 21 days afterwards.

Six of the ten confirmed no detectable dengue virus of their blood after being uncovered to the pathogen, in addition to no indicators that their immune system had responded to an infection by the virus over 85 days of monitoring.

Six folks in a placebo group, who had been additionally injected with dengue, all confirmed detectable virus when examined. Trial members obtained commonplace care from medical professionals the place crucial, and the virus used was a weakened model to minimise signs.

The constructive early information helps ongoing Part II trials of the tablet to stop the 4 various kinds of dengue in an actual world-setting the place the illness is widespread, J&J mentioned. The following step can be testing it as a remedy.

The drug works by blocking the motion of two viral proteins, stopping the virus from making copies of itself. It was well-tolerated by all trial members, J&J mentioned.

A key query for the longer term can be guaranteeing entry to the brand new drug, if it really works on a bigger scale, in lots of the low- and middle-income international locations the place it’s most wanted, an echo of the problem for the dengue vaccine the WHO backed earlier this month.

“We’re engaged on it,” mentioned Van Loock, including that it was early days.

(This story has been corrected to say that there have been six placebo group members, not 5, in paragraph 9)

Our Requirements: The Thomson Reuters Belief Rules.